![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Publication history |
Estratti |
Permessi |
Per citare questo articolo |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEW DIFFICULT CHALLENGES IN VASCULAR MEDICINE
Minerva Medica 2021 December;112(6):755-66
DOI: 10.23736/S0026-4806.21.07353-5
Copyright © 2021 EDIZIONI MINERVA MEDICA
lingua: Inglese
Cerebral venous thrombosis
Omri COHEN 1, 2, 3 ✉, Samuela PEGORARO 3, Walter AGENO 3
1 National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel-Hashomer, Israel; 2 Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; 3 Department of Medicine and Surgery, University of Insubria, Varese, Italy
Cerebral venous thrombosis (CVT) is a rare form of deep venous thrombosis (DVT), yet a leading cause of stroke in young adults, with an incidence that seems to be increasing in recent years. Risk factors for CVT overlap with those of DVT in other locations, with the addition of local risk factors, such as infections, head trauma and neurosurgery. The clinical presentation is highly variable, hence the diagnosis of CVT may be delayed or overlooked. Early recognition and timely initiation of anticoagulant treatment are of essence, while decompressive surgery can be lifesaving for patients with impending trans-tentorial herniation. Concomitant intracranial hemorrhage is not a contraindication to anticoagulant treatment. Endovascular treatment may be suggested for selected patients who deteriorate despite anticoagulant treatment. In this review we will provide an extensive and contemporary discussion of the incidence, pathophysiology, risk factors, clinical presentation, neuroimaging and management of CVT, in accordance with recent guidelines. Additionally, we will summarize the latest data with regards to direct oral anticoagulants (DOACs) treatment in CVT.
KEY WORDS: Venous thrombosis; Venous thromboembolism; Anticoagulants